Leap Therapeutics
LPTX
LPTX
37 hedge funds and large institutions have $24.1M invested in Leap Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
37% less funds holding
Funds holding: 59 → 37 (-22)
85% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 26
Holders
37
Holding in Top 10
–
Calls
$83K
Puts
$40K
Top Buyers
| 1 | +$2.89M | |
| 2 | +$2.32M | |
| 3 | +$2.2M | |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.91M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.62M |
Top Sellers
| 1 | -$1.36M | |
| 2 | -$269K | |
| 3 | -$155K | |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$89.9K |
| 5 |
DMKJ
David M. Knott Jr
|
-$84.8K |